tradingkey.logo

Pfizer Says Phase 3 Thrive-131 Study Did Not Meet Its Primary Endpoint

ReutersAug 15, 2025 4:34 PM

- Pfizer Inc PFE.N:

  • PFIZER: PHASE 3 THRIVE-131 STUDY DID NOT MEET ITS PRIMARY ENDPOINT -WEBSITE

  • PFIZER: INCLACUMAB WAS GENERALLY WELL TOLERATED IN THRIVE-131

Source text: [ID:]

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Related Articles

Tradingkey
KeyAI